Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21960849 | 0.77 | ALDH1A1 (0.57) | POLBALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL2428998 | 0.76 | HTT (0.56) | POLBALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL31280498 | 0.75 | POLB (0.47) | POLBALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL21964594 | 0.75 | POLB (0.40) | POLBMAPTSMN1; SMN2 | |
| SCHEMBL23880180 | 0.74 | ALDH1A1 (0.48) | POLBALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL23880184 | 0.74 | POLB (0.41) | POLBALDH1A1MEN1KMT2A | |
| SCHEMBL20555764 | 0.74 | HTT (0.50) | POLBALDH1A1MEN1KMT2AHTT | |
| SCHEMBL29200863 | 0.74 | HTT (0.50) | POLBALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL16061204 | 0.73 | POLB (0.45) | POLBALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL31105868 | 0.72 | HTT (0.49) | POLBALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-05 | — | — | US | disclosed |
| EP-3478675-B1 | HETEROAROMATIC DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | NFKBIA, IKBKG, IKBKE | POLB 1088/4885ALDH1A1 3872/4885MEN1 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.